About Alps Group Inc
https://alps-holdings.comAlps Group Inc is an integrated biotechnology platform providing research and development, medical services, and wellness solutions focused on advanced therapies. The company aims to create a fair healthcare ecosystem with accessible predictive, preventive, and precision medicine.
CEO
Seng Kong Tham
Compensation Summary
(Year )
Total Compensation (Unknown At The Moment)
Industry Biotechnology
Sector Healthcare
Went public October 31, 2025
Method of going public Reverse Merger
Full time employees 2
Ratings Snapshot
Rating : C
Discounted Cash Flow 1
Return On Equity 5
Return On Assets 1
Debt To Equity 1
Price To Earnings 1
Price To Book 1
Overall Score 2
Price Target
Target High $0
Target Low $0
Target Median $0
Target Consensus $0
Market Cap $162.24 M
52w High $2.90
52w Low $0.56
P/E -48.25
Volume 45.98K
Outstanding Shares 166.40M
About Alps Group Inc
https://alps-holdings.comAlps Group Inc is an integrated biotechnology platform providing research and development, medical services, and wellness solutions focused on advanced therapies. The company aims to create a fair healthcare ecosystem with accessible predictive, preventive, and precision medicine.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q2-2025 | $0 | $451.11K ▼ | $-893.9K ▼ | 0% | $-0.24 ▼ | $-435.39K ▲ |
| Q1-2025 | $0 | $483.92K ▲ | $-738.55K ▼ | 0% | $-0.2 ▼ | $-453.36K ▼ |
| Q4-2024 | $0 | $428.31K ▲ | $-269.21K ▼ | 0% | $-0.05 ▼ | $-168.08K ▼ |
| Q3-2024 | $0 | $337.59K ▼ | $-116.75K ▲ | 0% | $-0.02 ▲ | $26.15K ▲ |
| Q2-2024 | $0 | $469.61K | $-217.19K | 0% | $-0.04 | $-139.79K |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q2-2025 | $2.62M ▲ | $3.8M ▲ | $14.57M ▲ | $-10.77M ▼ |
| Q1-2025 | $3.47K ▼ | $3.62M ▼ | $10.88M ▼ | $-7.26M ▲ |
| Q4-2024 | $253.51K ▲ | $4.26M ▼ | $11.73M ▲ | $-7.46M ▼ |
| Q3-2024 | $65.22K ▼ | $29.94M ▲ | $9.97M ▲ | $19.97M ▼ |
| Q2-2024 | $143.15K | $29.56M | $9.48M | $20.08M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q2-2025 | $-893.9K ▼ | $-270.41K ▼ | $-130.89K ▲ | $420K ▲ | $2.61M ▲ | $-270.41K ▼ |
| Q1-2025 | $-738.55K ▼ | $-160.04K ▲ | $-180K ▼ | $90K ▲ | $-250.04K ▼ | $-160.04K ▲ |
| Q4-2024 | $-269.21K ▼ | $-281.71K ▼ | $26.71M ▲ | $-26.24M ▼ | $188.28K ▲ | $-281.71K ▼ |
| Q3-2024 | $-116.75K ▲ | $-197.93K ▲ | $-180K ▼ | $300K ▼ | $-77.93K ▼ | $-197.93K ▲ |
| Q2-2024 | $-217.19K | $-673.88K | $110.16K | $700K | $136.28K | $-673.88K |
CEO
Seng Kong Tham
Compensation Summary
(Year )
Total Compensation (Unknown At The Moment)
Industry Biotechnology
Sector Healthcare
Went public October 31, 2025
Method of going public Reverse Merger
Full time employees 2
Ratings Snapshot
Rating : C
Discounted Cash Flow 1
Return On Equity 5
Return On Assets 1
Debt To Equity 1
Price To Earnings 1
Price To Book 1
Overall Score 2
Price Target
Target High $0
Target Low $0
Target Median $0
Target Consensus $0